Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA

By The Northwire Desk — AI Analysis Mar 05, 2026 · 17:13 NLH · 0.345 Nova Leap Health Corp.
NLH · Price

Executive Summary

  • Nova Leap Health Corp. reported record‑high 2025 financial results, including $31.5 M of revenue (up 22.2% YoY) and Adjusted EBITDA of $2.05 M (up 31.0% YoY).
  • Consolidated gross profit margin improved to 39.7%, and operating income rose 28.1% to $1.11 M.
  • The company ended 2025 with $1.49 M cash, full access to a $1.09 M revolving credit facility, and $4.69 M of available acquisition credit, maintaining low leverage (1.02× Adjusted EBITDA).

Key Details

  • Revenue: $31.5 M for 2025 (↑22.2% from $25.8 M in 2024); Q4 2025 revenue $8.09 M (‑2.1% vs Q3 2025, +22.8% vs Q4 2024).
  • Adjusted EBITDA: $2,046,173 for 2025 (↑31.0% YoY); Q4 2025 Adjusted EBITDA $508,500 (↑23.1% YoY, ↓24.2% QoQ).
  • Gross Profit Margin: 39.7% in 2025 (up from 38.4% in 2024); Q4 2025 margin 39.8% (vs 39.6% in Q3 2025).
  • Operating Income: $1,105,998 for 2025 (↑28.1% YoY); Q4 2025 operating income $261,854 (down from Q3 2025 $418,553).
  • Net Loss/Income: Q4 2025 net loss of $53,728 (vs net income of $426,171 in Q3 2025 and $886,268 in Q4 2024).
  • Cash Position: $1,492,925 cash & equivalents as of Dec 31 2025.
  • Credit Facilities: Full access to unutilized revolving credit facility of $1,094,411 (CAD 1.5 M); up to $4,691,000 available for acquisitions under existing credit agreement.
  • Leverage: Total demand loans & promissory notes $2,091,468; leverage ratio 1.02× Adjusted EBITDA.
  • Accounts Receivable Collection Rate: 99.5% in 2025 (vs 99.4% in 2024).
  • Management Comment: CFO Chris LeBlanc highlighted the record performance, strong balance sheet, and readiness to fund organic growth and strategic acquisitions.

Notable Quotes

“2025 marked the strongest financial performance in Nova Leap’s history, with record results across both our Canadian and U.S. operations… Our disciplined financial management positions the Company well to continue investing in organic growth and strategic acquisitions in the future.” – Chris LeBlanc, Chief Financial Officer

Materiality: Material – Positive (significant earnings release indicating strong operational performance and ample liquidity for future growth).

Read the original news release →

More from Nova Leap Health Corp.

May 07, 2026 · 17:00

Nova Leap’s Q1 shines with record TTM revenue and a bolt-on Nova Scotia acquisition, but the small-cap story still needs to prove scalability beyond the home.

Earnings May 01, 2026 · 07:55

Nova Leap Executes Growth Strategy with Parkwood Acquisition, Boosting EBITDA by 28% While Tightening Liquidity

M&A / Property Mar 05, 2026 · 17:15

President & CEO Letter to Shareholders

Other Feb 02, 2026 · 14:22

Nova Leap sets up palliative care division in N.S.

Production / Operations Feb 02, 2026 · 07:00

Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

Production / Operations Dec 16, 2025 · 19:00

Nova Leap rolls out care management division in U.S.

Production / Operations